As a result, only one molecular therapy has so far been approved for use with RT, namely the anti-epidermal growth factor receptor (EGFR) antibody cetuximab in head and neck squamous cell carcinoma (HNSCC) [8, 9]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.